Price et al 1 have reported the results of the Gauging Responsiveness With a VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial in patients who had undergone percutaneous coronary intervention with Ն1 drug-eluting stents for the treatment of stable coronary artery disease or acute coronary syndrome at 83 sites in the United States and Canada. They reported that achievement of on-clopidogrel reactivity Ͻ208 P2Y12 reaction units at 12 to 24 hours after percutaneous coronary intervention/during follow-up was associated with a lower risk for cardiovascular events. 1 This is a well-designed clinical trial represented by multiple published articles. 2-3 The authors have analyzed and compared the effect of statins as a covariant in the previously published articles. 2 However, although the covariant effects of acute coronary syndrome presentation, diabetes mellitus, prior myocardial infarction, coronary artery bypass grafting, percutaneous coronary intervention, creatinine clearance, ␤-blocker at discharge, and total stent length were reported at 60 days and 6 months in the recent study, there is no result related to statin use and its covariant effect. 1 Statins show antiplatelet effects in patients with hypercholesterolemia and stable coronary artery disease. Ex vivo and in vivo evaluations showed lower platelet deposition, aggregate size, surface coverage, and collagen-induced platelet aggregation among statintreated patients. The authors of this article conclude that in acute myocardial infarction patients statins have an early antiplatelet effect in addition to that afforded by standard antiplatelet therapy. 4 Furthermore, clopidogrel (as a prodrug) requires hepatic cytochrome P450 metabolic activation to be converted to the active metabolite that is able to inhibit the platelet P2Y12 adenosinediphosphate receptor, decreasing platelet activation and aggregation processes. Statins, especially atorvastatin, have been identified that limit the ability of clopidogrel to inhibit platelet activation and aggregation processes in pharmacodynamic studies. 5 Collectively, it would be helpful if, in their conclusion, the authors were to provide more information on the intake of statins, types of statins used, analysis of covariant effect, and the impact of statins on study outcomes.
